Instituto de la Química y Metabolismo del Fármaco (IQUIMEFA), Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Consejo Nacional de Investigaciones Científicas y Técnicas (CONICET), Junín 956, Piso 3 (1113), Buenos Aires, Argentina.
Curr Pharm Des. 2023;29(6):394-406. doi: 10.2174/1381612829666221103093542.
Cannabis sativa L. has been used as medicine for thousands of years. Since the early identification of tetrahydrocannabinol (THC) in 1960, pharmacological activities were attributed to a group of unique structures named cannabinoids. For decades, research and development were applied to determine different cannabinoids and their medicinal properties. Nowadays there is evidence that the therapeutic benefits of the plant are based on the synergy of cannabinoids and other secondary metabolites such as terpenes and flavonoids. Differences between the medical performance of isolated compounds like cannabidiol (CBD) or THC and full-spectrum plant extracts are notable. Indeed, the superiority of the last one is provoked by the synergy between various different compounds. This improved medicinal effect is called the entourage effect. Chromatography has become the method of choice for the determination of cannabinoids, terpenes, and flavonoids, so it represents an excellent tool for a proper characterization of the plant and plant derived products. The objective of characterization relies not only in analyzing the fingerprint of cannabis, but also to identify different chemotypes for medical purposes. To understand the contributions of each natural product to this "entourage effect", this review presents an in-depth analysis of the utilization of High-performance liquid chromatography (HPLC), Gas chromatography (GC) and other methods for the analysis of phytocomponents of Cannabis sativa L. In this sense, a representative number of examples and advances made in the field together with limitations and future needs are provided. It can be concluded that standardized protocols and quality control policies and procedures are necessary for the comprehensive analysis of cannabis extracts and derivatives.
大麻已经被用作药物几千年了。自 1960 年首次鉴定出四氢大麻酚(THC)以来,药理学活性归因于一组名为大麻素的独特结构。几十年来,研究和开发一直致力于确定不同的大麻素及其药用特性。如今有证据表明,植物的治疗益处基于大麻素和其他次生代谢物(如萜烯和类黄酮)的协同作用。分离化合物(如大麻二酚(CBD)或 THC)和全谱植物提取物的医疗性能之间存在显著差异。事实上,后者的优越性是由各种不同化合物之间的协同作用引起的。这种改善的治疗效果被称为伴随效应。色谱法已成为测定大麻素、萜烯和类黄酮的首选方法,因此它是对植物和植物衍生产品进行适当特征描述的极好工具。特征描述的目的不仅在于分析大麻的指纹图谱,还在于确定不同的化学型用于医疗目的。为了了解每种天然产物对这种“伴随效应”的贡献,本综述深入分析了高效液相色谱(HPLC)、气相色谱(GC)和其他方法在大麻素分析中的应用。在这方面,提供了大量有代表性的例子和该领域的进展,以及局限性和未来需求。可以得出结论,对于大麻提取物和衍生物的综合分析,需要标准化的协议以及质量控制政策和程序。